In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Skin Care Line First For New Chapter Founder Schulick, Nutraceuticals In 2020

Executive Summary

New Chapter founder Paul Schulick will introduce skin masks, cleansers and lotions with Algatech's topical astaxanthin to maintain skin microbiome. He also plans to launch nutraceuticals once a non-compete agreement with P&G, the owner of his former firm New Chapter, expires in 2020.

You may also be interested in...



Health, Beauty And Wellness News: ByOM, Premier, Frutarom, Lactalis

New Chapter founders onto next chapter; French dairy firm acquires African pharma's formula business; 'Earth First' packaging for Premier Protein shakes; and Frutarom touts cognitive ingredient award for Neuravena.

New Chapter Founders' Vision Limited, Voice Stifled Under Parent Firm P&G

New Chapter founders Paul and Barbi Schulick leave and sever ties with parent firm Procter & Gamble six years after their company providing herbal products to US health food and vitamin stores was acquired by the global consumer health, personal and household care products marketer. Nature's Bounty adds Don Kerrigan, formerly in charge of US OTC drug marketing for Bayer and Pfizer, as its president for North America.

Recalls, Investments, Verifications: Health And Wellness Industry News

Supplements spiked with ED drugs recalled; Agritek Holdings purchases nutrition and supplement marketer Performance Nutrition Center; more dietary supplement recalls and other news in brief.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

RS148663

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel